In today’s briefing:
- APA Group Placement – Well Flagged Deal, but Lacks in Accretion
- 3P Learning (3PL): Steady Through the 3Rs, Eyes on FY24
- Recce Pharmaceuticals – R327 progressing in rapid infusion study
APA Group Placement – Well Flagged Deal, but Lacks in Accretion
- APA Group (APA AU) is looking to raise A$675m (US$430m) in its primary follow-on to partially fund its acquisition of the Alinta Energy assets in the Pilbara region.
- The deal is a well flagged one with APA having been one of the last remaining bidders on the asset. Short interest has been on the rise as well.
- However, the deal doesn’t seem accretive at our end, and the results reported today seemed to have missed analyst expectations.
3P Learning (3PL): Steady Through the 3Rs, Eyes on FY24
- Holistic Educational Suite: 3PL enriched its product portfolio, with the APAC debut of WritingLegends and BrightPath Assessement.
- Steady Financial Growth: Amidst challenges in the UK, 3PL’s 9% ARPU growth highlights its consistent performance and market strength.
- Setting the Pace: With attractive-priced offerings, an integrated product approach, and an innovative teacher training vision, 3PL is expected to continue growing its top line as more schools join.
Recce Pharmaceuticals – R327 progressing in rapid infusion study
Recce recently reported the completion of its data review from its earlier long-infusion Phase I study of the intravenous (IV) RECCE 327 (R327) formulation, confirming that the drug candidate shows favourable safety characteristics, a robust dose-dependent pharmacokinetic drug concentration response, as well as evidence of increased drug concentration into the urinary tract. The company is proceeding with a Phase I/II study assessing using a more rapid infusion rate, with recent completion of the first 2,500mg cohort of the Phase I part ahead of schedule. Obtaining financing is a near-term strategic priority given the cash at hand (A$1.6m at 30 June 2023), and the company’s current cash runway is short (into late Q3 CY23). Recce has signalled that it is seeking to raise A$12–15m. After rolling forward our estimates and updating forex assumptions, we obtain an rNPV valuation of A$562.4m (or A$3.15 per share), up from A$535.6m previously.